Sunil Sharma, MD
Hematology & Oncology · Salt Lake City, UTNPI 1699775767
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,495 of the $16,295 with a category attached, or 95.1%. 8 manufacturers reported payments, led by Stemline Therapeutics Inc. at 31.4% of the total. Reporting peaked in 2021 at $10,120 and has fallen 96.6% since, to $343 in 2025.
Across 13 payments — averaging $1253.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$5K
- Incyte Corporation$5K
- E.r. Squibb & Sons, L.L.C.$3K
- Mirati Therapeutics, Inc.$1K
- Celularity Inc.$1K
- Exelixis Inc.$732
- plus $68 from 2 others
Across 105 payments — averaging $14,078 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$666K
- Bristol Myers Squibb$526K
- Syndax Pharmaceuticals, Inc.$98K
- Takeda Pharmaceuticals U.S.A., Inc.$76K
- Novartis$56K
- Eli Lilly$33K
- plus $22K from 3 others
What the payments were for
- Consulting fees$15,49595%
- Travel & lodging$3892%
- Food & beverage$4113%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 2 | $5,120 |
| Incyte Corporation | 1 | $5,000 |
| E.r. Squibb & Sons, L.L.C. | 2 | $2,975 |
| Mirati Therapeutics, Inc. | 2 | $1,400 |
| Celularity Inc. | 1 | $1,000 |
| Exelixis Inc. | 3 | $732 |
| Eyepoint US, Inc. | 1 | $47 |
| AstraZeneca | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,295 in reported general payments places this provider in the 70th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$473K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
- Daanish HodaSalt Lake City$80K
- Tsewang TashiSalt Lake City$69K
- Finn PetersenSalt Lake City$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.